Jul 15, 2026· Comment from Parenteral Drug Association· FDA-2026-D-1255-0025
Filed as an attachment.
FDANonrulemakingFDA-2026-D-1255
Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing; Draft Guidance for Industry; Availability
RIN
—
Last modified
Jun 25, 2026
Comment window
closed 14d ago
Parenteral Drug Association filings
1
Activity
Parenteral Drug Association filed 1 comment on this docket between Jul 15, 2026 and Jul 15, 2026. 6 other organizations filed here. The comment window closed 14d ago.
What Parenteral Drug Association filed (1)
Abstract
No abstract recorded.
View on regulations.gov →Co-filers (6)
See everyone who commented →- Parenteral Drug AssociationTHIS ORG1 filing · confidence 97%
- Alliance for Regenerative Medicinetrade assoc.1 filing · confidence 85%
- American Society of Gene & Cell Therapytrade assoc.1 filing · confidence 85%
- Association for the Advancement of Blood & Biotherapiestrade assoc.1 filing · confidence 85%
- Eli Lilly and Companyunverified attribution1 filing · confidence 70%
- KROMATID INCunverified attribution1 filing · confidence 70%
- Testavec Ltdunverified attribution1 filing · confidence 70%